12 Month Price Forecast For EXAS
Distance to EXAS Price Forecasts
EXAS Price Momentum
🤔 Considering Exact Sciences (EXAS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 6:35 AM UTC
EXAS Analyst Ratings & Price Targets
Based on our analysis of 29 Wall Street analysts, EXAS has a consensus that is bullish. The median price target is $70.00, with forecasts ranging from $61.00 to $95.00. Currently, there are 21 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
With EXAS currently trading at $54.79, the median price forecast suggests a 27.8% upside. The most optimistic forecast comes from Kyle Mikson at Canaccord Genuity, projecting a 73.4% upside, while at provides the most conservative target, suggesting a 11.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EXAS Analyst Consensus
EXAS Price Target Range
Latest EXAS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EXAS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 13, 2025 | Benchmark | Bruce Jackson | Buy | Reiterates | $65.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $72.00 |
| Nov 26, 2024 | BTIG | Mark Massaro | Buy | Maintains | $75.00 |
| Nov 26, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $86.00 |
| Nov 11, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $75.00 |
| Nov 6, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $67.00 |
| Nov 6, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $82.00 |
| Nov 6, 2024 | Benchmark | Bruce Jackson | Buy | Maintains | $65.00 |
| Nov 6, 2024 | Craig-Hallum | Alex Nowark | Buy | Maintains | $65.00 |
| Nov 6, 2024 | BTIG | Mark Massaro | Buy | Maintains | $65.00 |
| Nov 6, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $75.00 |
| Nov 6, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $60.00 |
| Nov 6, 2024 | Stifel | Daniel Arias | Buy | Maintains | $67.00 |
| Nov 6, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $65.00 |
| Nov 6, 2024 | Jefferies | Brandon Couillard | Buy | Maintains | $85.00 |
| Nov 6, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $75.00 |
| Oct 30, 2024 | Bernstein | Eve Burstein | Outperform | Maintains | $90.00 |
| Oct 29, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $95.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $80.00 |
| Sep 26, 2024 | Raymond James | Andrew Cooper | Market Perform | Reiterates | $0.00 |
Stocks Similar to Exact Sciences Corp
The following stocks are similar to Exact Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Exact Sciences Corp (EXAS) Financial Data
Exact Sciences Corp has a market capitalization of $10.04B with a P/E ratio of -48.5x. The company generates $2.69B in trailing twelve-month revenue with a -8.0% profit margin.
Revenue growth is +12.8% quarter-over-quarter, while maintaining an operating margin of -2.6% and return on equity of -6.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Exact Sciences Corp (EXAS) Company Overview
About Exact Sciences Corp
Provides cancer screening and diagnostic tests.
The company generates revenue through the sale of its cancer screening and diagnostic products, including the Cologuard test for colorectal cancer detection and various Oncotype DX tests for breast and colon cancer. Additionally, Exact Sciences offers Covid-19 testing services, leveraging its expertise in diagnostics.
Exact Sciences has a strong focus on research and development, with a pipeline aimed at enhancing existing tests and creating new blood and fluid-based diagnostic solutions. The company has established partnerships with reputable institutions like MAYO Foundation and Johns Hopkins University, which may support its innovation and market presence. Founded in 1995, it is based in Madison, Wisconsin.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
6,500
CEO
Mr. Kevin T. Conroy J.D.
Country
United States
IPO Year
2001
Website
www.exactsciences.comExact Sciences Corp (EXAS) Latest News & Analysis
Exact Sciences Corp. presented clinical validation data for its OncodetectTM MRD test at ASCO GI, showing 78% sensitivity post-surgery and 91% during monitoring in the Alpha-CORRECT study.
The strong clinical validation results for Exact Sciences' Oncodetect MRD test could boost investor confidence, potentially leading to increased stock value and interest in the company's growth prospects.
Exact Sciences Corp. will present 11 abstracts at the ASCO GI meeting from January 23-25, 2025, highlighting advancements in cancer detection and diagnostics.
Exact Sciences' presentation of 11 abstracts at a major oncology symposium highlights its innovation in cancer diagnostics, potentially boosting investor confidence and impacting stock performance.
Exact Sciences stock fell 12% over four days due to increasing competition in colon cancer screening from Guardant Health and Natera.
Exact Sciences' stock decline indicates increasing competitive pressure in the colon cancer screening market, potentially impacting future revenue and market share, raising concerns for investors.
January often sees strong stock performance, but this should not be the sole reason for investment, as significant returns require longer-term strategies.
January performance alone doesn't guarantee long-term gains. Investors may misallocate funds based on seasonal trends, risking potential losses in the following months.
Exact Sciences Corp. (Nasdaq: EXAS) anticipates Q4 2024 revenue of $713 million, indicating strong performance and potential for future growth and profitability.
Exact Sciences' projected $713 million revenue for Q4 2024 signals robust performance and potential for growth, indicating strong market positioning and profitability prospects.
Exact Sciences Corp (EXAS) reported preliminary FY 2024 sales of $2.76 billion, a 10% increase year-over-year, surpassing consensus estimates of $2.74 billion.
Exact Sciences' stronger-than-expected sales growth signals robust demand and potential for profitability, positively influencing investor sentiment and stock performance.
Frequently Asked Questions About EXAS Stock
What is Exact Sciences Corp's (EXAS) stock forecast for 2025?
Based on our analysis of 29 Wall Street analysts, Exact Sciences Corp (EXAS) has a median price target of $70.00. The highest price target is $95.00 and the lowest is $61.00.
Is EXAS stock a good investment in 2025?
According to current analyst ratings, EXAS has 21 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $54.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for EXAS stock?
Wall Street analysts predict EXAS stock could reach $70.00 in the next 12 months. This represents a 27.8% increase from the current price of $54.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Exact Sciences Corp's business model?
The company generates revenue through the sale of its cancer screening and diagnostic products, including the Cologuard test for colorectal cancer detection and various Oncotype DX tests for breast and colon cancer. Additionally, Exact Sciences offers Covid-19 testing services, leveraging its expertise in diagnostics.
What is the highest forecasted price for EXAS Exact Sciences Corp?
The highest price target for EXAS is $95.00 from Kyle Mikson at Canaccord Genuity, which represents a 73.4% increase from the current price of $54.79.
What is the lowest forecasted price for EXAS Exact Sciences Corp?
The lowest price target for EXAS is $61.00 from at , which represents a 11.3% increase from the current price of $54.79.
What is the overall EXAS consensus from analysts for Exact Sciences Corp?
The overall analyst consensus for EXAS is bullish. Out of 29 Wall Street analysts, 21 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $70.00.
How accurate are EXAS stock price projections?
Stock price projections, including those for Exact Sciences Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
